Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products ...

(RTTNews) - Eli Lilly And Co. (LLY) filed lawsuits Tuesday against Strive Pharmacy and Empower Pharmacy, accusing them of unlawfully compounding and selling tirzepatide, the active ingredient in ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...